CRISPR Therapeutics AG (CRSP) Operating Expenses (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Operating Expenses of $131.7 million for Q1 2026, down 15.37% sequentially from $155.6 million in Q4 2025, and down 11.78% YoY from $149.3 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) Operating Expenses (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Operating Expenses for 12 years, with the latest figure at $131.7 million in Q1 2026.
- Quarterly Operating Expenses fell 11.78% year-over-year to $131.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $650.5 million (up 27.03% YoY) and the FY2025 annual result came in at $668.1 million, up 32.59% from the prior year.
- Operating Expenses retreated to $131.7 million in Q1 2026 per CRSP's latest filing, from $155.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $230.2 million in Q2 2025 and troughed at $100.3 million in Q4 2024.
- A 5-year average of $151.3 million and a median of $149.3 million in 2025 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses dropped 27.44% in 2023, then jumped 55.2% in 2025.
- Over 5 years, Operating Expenses stood at $131.5 million in 2022, then gained by 0.06% to $131.6 million in 2023, then slipped by 23.81% to $100.3 million in 2024, then surged by 55.2% to $155.6 million in 2025, then decreased by 15.37% to $131.7 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $131.7 million, $155.6 million, and $132.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | 127.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 127.45 Mn |
| Mar 31, 2026 | 131.71 Mn |
| Dec 31, 2025 | 155.63 Mn |
| Sep 30, 2025 | 132.95 Mn |
| Jun 30, 2025 | 230.22 Mn |
| Mar 31, 2025 | 149.29 Mn |
| Dec 31, 2024 | 100.28 Mn |
| Sep 30, 2024 | 110.73 Mn |
| Jun 30, 2024 | 151.78 Mn |
| Mar 31, 2024 | 141.09 Mn |
| Dec 31, 2023 | 131.62 Mn |
| Sep 30, 2023 | 132.41 Mn |
| Jun 30, 2023 | 165.22 Mn |
| Mar 31, 2023 | 164.49 Mn |
| Dec 31, 2022 | 131.55 Mn |
| Sep 30, 2022 | 182.48 Mn |
| Jun 30, 2022 | 183.42 Mn |
| Mar 31, 2022 | 176.91 Mn |
| Dec 31, 2021 | 158.60 Mn |
| Sep 30, 2021 | 129.67 Mn |